Wyeth Warns on Drug Delay--and Confuses Investors
This article was originally published in RPM Report
It isn't getting any easier to interpret the significance of FDA's decisions to schedule--or skip--an advisory committee meeting. Wyeth CEO Bob Essner made that task all the more difficult when he alluded to a new policy at FDA requiring advisory committees for all psychiatric drug products. FDA says there is no new policy, but Wyeth's antidepressant desvenlafaxine is likely to face approval delays for another reason altogether: manufacturing problems.
You may also be interested in...
FDA's advisory committee process has long been criticized for conflict of interest issues. But now those on the inside are questioning whether change is needed. At the same time, some FDA officials don't believe advisory committees add much to the review process. And given resource constraints, FDA is holding committees less and less often. That may be good news for drug sponsors. The public disclosure of an NDA as part of the committee process leaves sponsors vulnerable to attacks that can undermine the future of a drug. Given the sway advisory committees in the court of public opinion, a re-examination of the system is coming.
Peter Marks predicts that staffing challenges within CBER can be alleviated by offering employees the flexibility to work remotely – permanently. With important posts in the vaccines office still to be hired, it could be an important incentive.
Former FDA principal deputy commissioner Amy Abernethy says cell and gene therapy is an area primed for improved ‘parallel conversation’ between FDA and CMS on data requirements.